Rejuveron Telomere Therapeutics is a pre-clinical seed-stage company focused on promoting healthy aging by improving telomere function. It has established research collaborations with world-class academics and clinical researchers that aim to advance our understanding of telomere function and support the development of effective therapies. The primary goal is to develop small molecule therapies that restore telomere length in a variety of diseases, with the lead indications being Dyskeratosis Congenita and Idiopathic Pulmonary Fibrosis. Rejuvenating prematurely damaged or shortened telomeres through a novel mechanism of action constitutes the underlying strategy.